Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_3

33%

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 31 (33.3%)

N/A2 (66.7%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_3

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03001817

completednot_applicable

Lipid Biomarkers for Diabetic Heart Disease

NCT01752842

terminatednot_applicable

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT00252499

Clinical Trials (3)

Showing 3 of 3 trials

NCT03001817Phase 3

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Completed

NCT01752842Not Applicable

Lipid Biomarkers for Diabetic Heart Disease

Completed

NCT00252499Not Applicable

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3